Granaticin B

DelveInsight's latest report reveals a robust B-cell lymphoma pipeline with over 295 companies developing 300+ therapies, highlighting significant industry investment in this area.

Lin BioScience's investigational drug LBS-007 has been granted Fast Track Designation by the U.S. FDA for treating acute myeloid leukemia, highlighting its potential to address unmet medical needs in acute leukemia treatment. The company is conducting a Phase 1/2 trial in patients with relapsed or resistant acute leukemias across the US, Australia, and Taiwan.

Lin BioScience's LBS-007 has been granted Fast Track Designation by the FDA for acute myeloid leukemia (AML) treatment, expediting its development.

Capivasertib plus abiraterone and ADT shows improved radiographic progression-free survival in PTEN-deficient metastatic hormone-sensitive prostate cancer.

The FDA issued a CRL for Atara Biotherapeutics' tabelecleucel due to third-party manufacturing issues, not efficacy or safety data, delaying potential approval for EBV+ PTLD.